A SENSITIVE INDICATOR FOR THE SEVERITY OF COVID-19: THIOL Abstract Background/aim: Thiol status is a good reflector of the cellular redox and have vital roles in various cellular signaling pathways.The purpose of the study was to investigate thiol status in patients with SARS-CoV-2 infection. A total of 587 subjects (517 patients/70 healthy controls) were enrolled in the study.The patients were categorized into the groups regarding to the severity of disease (mild, moderate, severe, and critical).Thiol status of all groups were compared. The patients had significantly diminished thiol levels compared to controls.Thiol levels were gradually decreased as the severity of the disease increased.Logistic regression analyses identified that thiol concentrations were an independent risk factor for the disease severity in each phase (mild group OR 0.975, 95%CI 0.965-0.986; moderate group, OR 0.964, 95%CI 0.953-0.976; severe group OR 0.953, 95%CI 0.941-0.965; critical group OR 0.947, 95%CI 0.935-0.960).Thiol test exhibited the largest area under the curve at 0.949, with the highest sensitivity (98.6%) and specificity (80.4%). Depleted thiol status was observed in SARS-CoV-2 infection.Decline of the thiol levels by degrees while the severity of infection increased was closely related to the progression of the disease.This outcome highlights that thiols could be an impressible biomarker for predicting of the severity of COVID-19. Key words: COVID-19, inflammation, immune response, severity, thiol.
17 August 2014 in Journal of Clinical Laboratory Analysis
Nitric oxide synthase (NOS) is present in the brain and cerebral arteries and it enables the synthesis of nitric oxide (NO), which plays a critical role in brain perfusion. Asymmetrical dimethylarginine (ADMA) is an endogenous NOS inhibitor. The aim of this study was to evaluate serum ADMA levels, which are an indicator of endothelial dysfunction of the renal functions in patients with acute ischemic stroke, and to determine whether there is a possible correlation between ADMA and NO levels and the l-arginine-to-ADMA ratio. Fifty-two patients (22 male and 30 female; mean age: 75.2 ±10.1 years) with a diagnosis of acute ischemic stroke in the first 24 h post-stroke and 48 healthy individuals (controls; 13 male and 35 female; mean age: 60.1 ±7.92 years) were included in this study. The risk factors recorded and evaluated were age and gender of the patients, serum lipid levels, serum ADMA levels, nitrate-to-nitrite ratios, l-arginine, l-arginine-to-ADMA ratios, sedimentation rate, C-reactive protein (CRP), urea and creatinine levels, and glomerular filtration ratio (eGFR). The mean serum ADMA level was 0.48 ±0.23 μM for the patients and 0.36 ±0.18 μM for the controls. The mean NO level was 2.78 ±0.59 μM for the patient group and 4.49 ±2.84 μM for the controls. The ADMA levels for the patient group were significantly higher than for the control group (p = 0.011); the NO levels for the patients were significantly lower than for the controls (p < 0.001). The logistic regression method demonstrated that ADMA and NO levels may be independent risk factors for the patient group, and the receiver operating characteristic (ROC) curve analysis showed that both of these variables were discriminative risk factors. An increased serum level of the NOS inhibitor ADMA was found to be a possible independent risk factor for ischemic stroke.